Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2009 Mar;16(2):112-23.
doi: 10.1097/MOH.0b013e3283257a87.

Second hematopoietic stem cell transplantation in myeloid malignancies

Lisa M Arfons  1 , Marcie Tomblyn, Vanderson Rocha, Hillard M Lazarus
Affiliations
Review

Second hematopoietic stem cell transplantation in myeloid malignancies

Lisa M Arfons et al. Curr Opin Hematol. 2009 Mar.

Abstract

Purpose of review: Hematopoietic stem cell and umbilical cord blood transplantation can be a life-saving procedure for many patients with myeloid malignancies. The posttransplant period, however, can be complicated by graft failure and disease relapse, prompting the need for further therapy. Herein, we review and examine the data of second allogeneic stem cell transplant after autologous, allogeneic and umbilical cord blood transplantation.

Recent findings: Although large, prospective, multicenter trials are lacking, certain factors such as younger patient age, lower disease burden and a longer interval between first transplantation and relapse appear to portend a better prognosis for second transplant.

Summary: Currently, only a selected group of patients without important comorbidities should be considered for second allogeneic transplantation. Strategies such as new immunosuppressive agents, antileukemia monoclonal antibodies, graft modification and use of molecularly targeted therapy are needed to decrease the morbidity and increase the efficacy of transplantation.

PubMed Disclaimer

Conflict of interest statement

Disclosures: L. Arfons, M. Tomblyn, V. Rocha and H. Lazarus have no conflicts of interest.

Comment in

  • Myeloid disease.
    Tallman MS. Tallman MS. Curr Opin Hematol. 2009 Mar;16(2):63. doi: 10.1097/MOH.0b013e3283279a76. Curr Opin Hematol. 2009. PMID: 19468265 No abstract available.

References

    1. Wolff SN. Second hematopoietic stem cell transplantation for the treatment of graft failure, graft rejection or relapse after allogeneic transplantation. Bone Marrow Transplant. 2002;29:545–552. - PubMed
    1. Liesveld JL, Rothberg PG. Mixed chimerism in SCT: conflict or peaceful coexistence? Bone Marrow Transplant. 2008;42:297–310. This review discusses the different methods of chimerism analysis, and the role of chimerism in both malignant and non-malignant disease states. The authors also discuss the role of graft type, lineage-specific chimerism and the clinical application of the analysis. - PubMed
    1. Guardiola P, Kuentz M, Garban F, et al. Second early allogeneic stem cell transplantations for graft failure in acute leukaemia, chronic myeloid leukaemia and aplastic anemia. Br J Haematol. 2000;111:292–302. - PubMed
    1. Narimatsu H, Kami M, Miyakoshi S, et al. Graft failure following reduced-intensity cord blood transplantation for adult patients. Br J Haematol. 2005;132:36–41. - PubMed
    1. Fernandes J, Rocha V, Robin M, et al. Second transplant with two unrelated cord blood units for early graft failure after haematopoietic stem cell transplantation. Br J Haematol. 2007;137:248–251. - PubMed

MeSH terms

Substances